US Public Health Spending on Biosimilars: a data driven analysis

US Public Health Spending on Biosimilars: a data driven analysis

Which companies and products are shaping the US biosimilar public health spending sector?

Biosimilars are a useful way to contain pharmaceutical expenditure for both payers and patients. By the end of 2020, the FDA had approved 29 biosimilar products for eight different original biologic products. Of these, 18 had been launched by the end of that year with many more in the pipeline. So, which companies are enjoying success? How are biosimilars impacting reference products? Which biosimilars have been approved but not yet launched? The answers can be found in this report based on a detailed examination of Medicare and Medicaid spending.

Companies

Amgen, Novartis, Teva, Roche, AstraZeneca, Pfizer, Merck & Co., Genentech, Daiichi Sankyo, Boehringer Ingelheim, Sandoz, Celltrion, Samsung Bioepis, Janssen, Amneal Pharmaceuticals, Coherus, Johnson & Johnson, Viatris, Fresenius Kabi, Cephalon, Kashiv BioSciences